Summit, New Jersey based Celgene Corporation and Receptos, Inc. of San Diego, California, a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, have announced their joint signing of a definitive agreement in which Celgene will acquire Receptos. Under terms of the merger agreement,…
Receptos
Clinical investigators worldwide are beginning to recruit 1,200 patients with relapsing multiple sclerosis for a study assessing the effectiveness of two different doses of RPC1063 (Receptos, Inc.), an experimental oral therapy, and Avonex® (interferon beta-1a, Biogen Inc.) in order to reduce relapse rate in patients. This study, called the Sunbeam Study, is being funded by…
Biopharmaceutical company Receptos, Inc. has enrolled the first participant with relapsing multiple sclerosis (RMS) in its SUNBEAM phase 3 trial, which will evaluate the potential therapy RPC1063 in patients who suffer from the disease. The company’s phase 3 RADIANCE trial, also…
Biopharmaceutical company Receptos, Inc. is enrolling the first patient in their SUNBEAM phase 3 trial to evaluate the company’s investigational therapy for the treatment of patients with relapsing multiple sclerosis (RMS) and ulcerative colitis (UC), called RPC1063. In addition, Receptos has recently started its phase 3 …
Biopharmaceutical company Receptos, Inc. announced that they will review data from the phase 2 portion of the RADIANCE trial, the company’s phase 2 / 3 study testing RPC1063 in the treatment of Relapsing Multiple Sclerosis (RMS). The data is being presented at the largest meeting dedicated to multiple sclerosis…
Following the promising results of prior trials, Receptos, Inc., a biopharmaceutical company engaged in the treatment of immune and metabolic diseases, announced that the Phase 2 portion of the RADIANCE trial has met the primary endpoint, a reduction in MRI brain lesion activity in patients with relapsing multiple sclerosis…